Detalhe da pesquisa
1.
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma.
Invest New Drugs
; 39(4): 1081-1088, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33660194
2.
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.
Invest New Drugs
; 39(4): 1057-1071, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624233
3.
Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Clin Cancer Res
; 29(17): 3320-3328, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37382656
4.
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer.
Front Oncol
; 13: 1178313, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37274265
5.
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res
; 28(11): 2237-2247, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363301
6.
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.
Clin Cancer Res
; 27(10): 2773-2781, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33441294
7.
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
Mol Cancer Ther
; 20(1): 132-141, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33177152
8.
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
J Immunother
; 44(7): 264-275, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928928
9.
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Clin Cancer Res
; 27(5): 1267-1277, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33229456
10.
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors.
Clin Cancer Res
; 27(23): 6393-6404, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465599
11.
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
Clin Cancer Res
; 27(8): 2168-2178, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33514524
12.
Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors.
J Pancreat Cancer
; 6(1): 21-31, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32219196